Tag: GlobeNewswire

Expansion Brings Total Deployments with Existing Customer to Nine Properties, with Plans to Scale Across Its Entire Portfolio Through 2027

PALO ALTO, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Cloudastructure, Inc. (“Cloudastructure” or the “Company”) (NASDAQ: CSAI), a leader in cloud-native AI surveillance and remote guarding, today announced the expansion of its deployment with an existing customer, a housing partner with a portfolio spanning multifamily and senior living communities. The expansion adds two additional properties, bringing the total number of properties utilizing Cloudastructure’s platform to nine. The customer plans to continue expanding its use of Cloudastructure, with the goal of deploying the platform portfolio wide across approximately 23 properties by the end of 2027.

The two new communities represent the eighth and ninth properties deployed with this housing partner. At the affordable housing community, Cloudastructure will deploy a total of 10 cameras, including eight existing cameras and two new ones, along with three speakers, with seven cameras utilizing active monitoring and three utilizing AI-powered surveillance. At the senior living community, Cloudastructure will modernize a 45-camera environment, with 25 cameras utilizing Live View and the remaining 20 utilizing a combination of Remote Guarding and AI-powered surveillance. The two configurations reflect a single cloud-native platform matching AI-powered surveillance, Live View and Remote Guarding to the requirements of each asset. As geographically distributed communities with extensive common areas and limited on-site staffing, multifamily and senior living properties are a natural fit for cloud-native, proactive security.

“The security industry is working through a generational shift away from hardware-centric, reactive systems and toward cloud-native AI platforms, and portfolio owners are where that shift shows up first,” said James McCormick, Chief Executive Officer of Cloudastructure. “When adding a property does not require new proprietary hardware or a new long-term contract, expansion stops being a procurement project and becomes an operating decision. That is why these relationships tend to grow property by property.”

McCormick continued, “Residential portfolios are rarely uniform. A conventional community and a senior living campus carry very different requirements, and a cloud-native platform lets an owner match the level of intervention to each asset rather than standardize on the most expensive option everywhere. As owners consolidate onto one platform, we expect each incremental property to become a simpler decision, and we expect that pattern to continue across the verticals we serve.”

With approximately 14 additional properties representing potential future deployments within this customer’s current portfolio, the relationship illustrates Cloudastructure’s strategy of establishing its platform within individual properties and expanding those relationships across broader customer portfolios. Across customer deployments, Cloudastructure has reported a 98% deterrence rate against criminal activity and customer retention of approximately 99%. Management believes these performance metrics support the portfolio wide expansion opportunity described above.

About Cloudastructure
Headquartered in Palo Alto, California, Cloudastructure’s patented, advanced, award-winning security platform utilizes a scalable cloud-based architecture that features cloud video surveillance with proprietary, state-of-the-art AI/ML analytics, and a seamless remote guarding solution. The combination enables enterprise businesses to achieve proactive, end-to-end security, and pairs that platform with an attractive value proposition that eschews proprietary hardware and offers contract-free, month-to-month pricing and unlimited 24/7 support. With Cloudastructure, companies can achieve unparalleled situational awareness in real time and thereby stop crime as it is happening, while simultaneously achieving up to a 75% lower Total Cost of Ownership than other systems. For more information, visit https://www.cloudastructure.com/.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking, such as statements containing estimates, projections, and other forward-looking information. Forward-looking statements are typically identified by words and phrases such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “seek,” “should,” “will,” “would,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target” or the negative of such words and other comparable terminology. However, the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and involve risks, uncertainties, and other factors beyond our control. Therefore, we caution you against relying on any of these forward-looking statements. Factors that could cause or contribute to such differences include the risks and uncertainties discussed in the reports that the Company has filed with the SEC, such as its Annual Report on Form 10-K. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement. Except as required by applicable law, including U.S. federal securities laws, we do not intend to update any of the forward-looking statements to conform them to actual results or revised expectations.

Media Contact
Kathleen Hannon, Sr. Communications Director
Cloudastructure, Inc.
704.574.3732
Kathleen@cloudastructure.com

Investor Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Cloudastructure@KCSA.com

STS Technocrat (India) Pvt. Ltd. signs a leading pharmaceutical customer and is building an integrated SteraMist iHP enclosure with TOMI to support growth across India

FREDERICK, Md. , Oct. 01, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.^® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced growing adoption of SteraMist iHP technology in India’s pharmaceutical sector through its partner, STS Technocrat (India) Pvt. Ltd.

STS Technocrat (India) Pvt. Ltd. is one of India’s leading providers of technology solutions for the pharmaceutical, healthcare, food and beverage, cosmetics, and HoReCa (hotel, restaurant and catering) industries. In addition to distributing SteraMist, STS Technocrat (India) Pvt. Ltd. is working with TOMI to manufacture a turnkey, fully integrated SteraMist iHP enclosure.

STS Technocrat (India) Pvt. Ltd. recently signed a well-known pharmaceutical company as a SteraMist customer. This win gives SteraMist a strong reference site in the region, and STS Technocrat (India) Pvt. Ltd. is already building on it with several more opportunities in the pharmaceutical sector. In the United States, customer referrals have been one of the strongest drivers of SteraMist iHP adoption across life sciences, and TOMI expects the same pattern in India as STS Technocrat (India) Pvt. Ltd. expands its reach.

India is one of the world’s fastest-growing pharmaceutical markets. According to iMarc group, the market grew from USD 68.38 billion in 2025 to USD 75.89 billion in 2026. The market is projected to reach USD 174.67 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.98% from 2026 to 2034. As manufacturers scale production and align with global GMP standards, demand for validated, low-downtime decontamination continues to grow.

“We are making strong strides in the Indian market with SteraMist iHP decontamination technology,” said Sachin Utekar, Director of STS Technocrat (India) Pvt. Ltd. “We already have an established client base that aligns well with SteraMist iHP decontamination technology. We look forward to continuing our collaboration with TOMI on the integrated SteraMist iHP enclosure and expanding across the region.”

For more information about SteraMist and TOMI Environmental Solutions, visit SteraMist.com.

About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®

TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company providing environmental disinfection and bio-decontamination solutions through manufacturing, sales, and licensing of its Binary Ionization Technology® (BIT®) platform. Developed under a defense grant with DARPA, BIT® utilizes low-percentage hydrogen peroxide to produce ionized hydrogen peroxide (iHP®) fog. SteraMist® products serve hospitals, laboratories, government and military installations, cruise ships, office buildings, schools, restaurants, food processing facilities, and residences, delivering protection against a broad range of bacteria, viruses, mold, mycotoxins, and biological and chemical warfare agents. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s products and services to serve the life sciences sector. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT: 
John Nesbett/Zach Nevas
IMS Investor Relations 
tomi@imsinvestorrelations.com

Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline

SEATTLE and VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Benjamin Halladay, CPA, as Chief Financial Officer, effective October 5, 2026. He will be responsible for the Company’s financial strategy, accounting, investor relations, information technology, and other key administrative functions. 

Mr. Halladay joins Achieve from Esperion Therapeutics, a commercial-stage pharmaceutical company with more than $400 million in annual revenue, where he served as Chief Financial Officer from November 2022 until July 2026. During his tenure, Esperion deleveraged its balance sheet and acquired Corstasis Therapeutics and its product Enbumyst. He led the finance workstream through the company’s sale to ARCHIMED for up to $1.1 billion. As announced by Esperion, the upfront cash consideration represented a premium of 58% to its closing share price on April 30, 2026. Mr. Halladay brings more than 15 years of financial management experience across commercial and launch environments, with earlier positions at Pfizer Inc., where he worked on Lipitor and Chantix in the Primary Care business unit, and at National Oilwell Varco, a Fortune 500 global industrial company.

“Ben has helped scale a commercial pharma organization and expand its portfolio through business development within its existing capital structure,” said Andrew D. Goldberg, MD, Chief Executive Officer, Achieve. “He has run the finance function as a public company CFO, and began his biopharma finance career in large-cap pharma. As we move toward potential commercialization of cytisinicline, that combination of capital efficiency and operating experience is exactly what this stage demands.”

“The discipline that determines how a launch goes is put in place long before the first prescription is written,” said Mr. Halladay. “That is the work I’m excited to do. Achieve is developing a medicine that could change what quitting looks like for millions of people, and my job is to build the financial and operating foundation that supports it, on schedule and on plan.”

Mr. Halladay holds an MBA from Fordham University and a BA from Syracuse University, and is a Certified Public Accountant (inactive).

Mark Oki will step down as Chief Financial Officer of Achieve, effective October 5, 2026, and Mr. Halladay succeeds him in the role. Mr. Oki served as Chief Financial Officer through Achieve’s Phase 3 program and NDA submission, and the Company thanks him for his contributions.

ABOUT ACHIEVE LIFE SCIENCES, INC.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

ABOUT CYTISINICLINE
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Tobacco use is currently the leading cause of preventable death, responsible for more than seven million deaths worldwide and nearly half a million deaths in the United States annually.²^,³

In addition, there are nearly 18 million adults in the United States who use e-cigarettes, also known as vaping.¹ In 2025, approximately 1.4 million middle and high school students in the United States reported using e-cigarettes.⁴ There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded Achieve the Commissioner’s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine dependence for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products.

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements regarding the timing and outcome of Achieve’s planned NDA resubmission for cytisinicline, the timing of any FDA decision, the potential benefits of cytisinicline, the potential market for cytisinicline, the Company’s commercialization plans and readiness, and the anticipated benefits of new executive leadership. Achieve may not achieve its plans, projections, or other expectations and may not be able to successfully complete its NDA resubmission or obtain regulatory approval for cytisinicline on the anticipated timeline or at all. These statements are based on management’s current expectations and beliefs and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those detailed in Achieve’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Achieve undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACT
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
media@achievelifesciences.com
425-686-1510

REFERENCES
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.
²World Health Organization. WHO Report on the Global Tobacco Epidemic, 2025. Geneva: World Health Organization; 2025.
³U.S. Department of Health and Human Services. The Health Consequences of Smoking, 50 Years of Progress. A Report of the Surgeon General. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
⁴Eunice Park-Lee, Lauren M Dutra, Hannah Cowan, et al. Tobacco Product Use Among Middle and High School Students in the United States: National Youth Tobacco Survey, 2025, Nicotine & Tobacco Research, 2026; ntag116, doi.org/10.1093/ntr/ntag116.

Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers

Agreement establishes a 10-year commercial framework covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, anchored by an initial 100-device commercialization program and minimum revenue thresholds payable to Nexalin to maintain exclusivity

Binding initial purchase order at signing and a clinical pilot targeted within 90 days, supporting a distributor-funded manufacturing framework that is designed to generate recurring royalty revenue on every device and every disposable placed into the market

HOUSTON, TX, Oct. 01, 2026 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has signed a definitive international distribution agreement (the “Agreement”) with Inovanexa Medical Technologies S.A. (the “Distributor”), appointing the Distributor as Nexalin’s exclusive distributor for the importation, distribution, commercialization, promotion and sale of the Company’s Nexalin Sync™ non-invasive neurostimulation device — which has been approved by Brazil’s National Health Surveillance Agency (ANVISA) for the treatment of anxiety, depression and insomnia — across Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, a combined territory of more than 300 million people. The Agreement formalizes and supersedes the Letter of Intent entered by the parties in February 2026 and carries an initial 10-year term, with successive 10-year renewals subject to performance.

The Agreement converts more than two years of deliberate groundwork in Brazil — ANVISA regulatory approval of the Nexalin Sync device, a completed clinical trial at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo that reported a 77.8% anxiety response rate, and award-winning investigator research — into a definitive commercial launch platform for South America. Brazil is one of the ten largest economies in the world, with a population in excess of 215 million, of whom more than 35 million are estimated to be affected by mental health disorders.

Key terms of the Agreement include:

• Exclusive rights across seven countries. The Distributor is appointed as Nexalin’s exclusive distributor across Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela, subject to defined performance requirements, and is authorized to operate under the trade name “Nexalin LATAM.”
• Immediate, binding initial order and rapid clinical ramp-up. The Distributor is required to place an initial binding purchase order for 10 Nexalin Sync devices with 5 delivered immediately and then deploying the initial devices in a clinical pilot program in Brazil targeted to launch within 90 days.
• Initial 100-device commercialization program. The Agreement establishes a structured pricing framework for the first 100 Nexalin Sync devices, together with a mechanism for larger strategic transactions with government and private-sector customers, including equal profit-sharing on qualifying private-sector transactions involving devices assembled in Brazil.
• Royalty-bearing local manufacturing — at zero capital cost to Nexalin. Upon the purchase of the first 30 devices, the Distributor is required to establish a local manufacturing facility in Brazil entirely at its own cost, operating under Nexalin’s technical supervision and aligned with FDA-compatible quality standards. Nexalin is entitled to receive fixed per-device compensation for each locally manufactured device placed into the marketplace, together with a per-unit royalty on every locally manufactured disposable electrode sold, which is intended to create a recurring, usage-driven revenue stream.
• Full access to government and public-sector channels. The Distributor is authorized to pursue federal, state and municipal tenders and procurement opportunities, as well as public hospitals and universities, in Brazil — home to one of the largest government-run public healthcare systems in the world — and throughout the territory.
• Nexalin retains full ownership of all intellectual property. Nexalin remains the sole and exclusive owner of all intellectual property, technology, know-how, patents and trademarks relating to the Nexalin Sync platform, and all encrypted circuit boards required for the devices to function will be loaded, encrypted and supplied exclusively by Nexalin.

“This Agreement is the commercial culmination of everything we have methodically built in Brazil — and the launch pad for all of South America,” said Mark White, Chief Executive Officer of Nexalin Technology. “We secured ANVISA approval, we generated compelling clinical data at one of Latin America’s most prestigious psychiatric research institutions, and we said we would convert that foundation into a definitive commercial partnership. Today we have done exactly that. This is a 10-year exclusive framework across seven countries and more than 300 million people, with a binding initial order placed at signing.”

Mr. White continued, “We believe this Agreement marks the inflection point Nexalin has been working toward — the shift from a pre-revenue research and development company to a revenue-producing global distribution company. The economics are capital-light by design: our partner funds the buildout while Nexalin retains intellectual property, supplies the encrypted boards at the core of every device, and earns revenue on every device and every disposable placed into the market. This Agreement gives Nexalin a scalable business plan with a non-invasive, drug-free treatment platform — while establishing a repeatable blueprint for international markets alongside our ongoing FDA De Novo pathway in the United States.”

“Brazil is the template, not the exception. We have strengthened our leadership specifically to execute against that blueprint, most recently with the addition of Robert DiTota as Senior Strategic Advisor, Global Commercialization. His mandate is to help us structure and execute distribution partnerships of this caliber across North America, South America and Europe. We now have the clinical foundation, the intellectual property, the regulatory pathway and the commercial leadership to scale it.”

“Nexalin has done something very few medical technology companies attempting to enter Brazil ever accomplish it arrived with regulatory approval already in hand and clinical results generated at the University of São Paulo, one of the most respected psychiatric research institutions in Latin America,” said Dr. Raphael Luz Pereira Romano, the Chief Medical Officer of Inovanexa Medical Technologies S.A. “Mental health is one of the most urgent public health priorities across our region, and access to safe, non-invasive, drug-free treatment options remains severely limited. We are committing our capital, our regulatory expertise and our commercial infrastructure — including local manufacturing in Brazil — because we believe the Nexalin Sync platform can become a new standard of care across the territory. Our immediate focus is executing the clinical pilot program and building the foundation for scale across both the private and public healthcare sectors.” 

Under the Agreement, the Distributor is responsible for all costs associated with importation, regulatory compliance, marketing and local manufacturing. Exclusivity, renewal and the local manufacturing framework are subject to the Distributor’s satisfaction of the performance requirements and other terms and conditions set forth in the Agreement, and there can be no assurance that the Distributor will meet such requirements, that purchase orders beyond the initial binding order will be placed, or that the commercial objectives of the Agreement will be achieved.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. Nexalin’s medical devices are non-invasive and undetectable to the human body. Nexalin products are developed to provide relief to those afflicted with mental health issues using frequency based bioelectronic medical technology. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). These forward-looking statements relate to future events, future performance, or management’s current expectations, beliefs, assumptions, plans, estimates, intentions, or projections relating to the future, and are not guarantees of future performance. Any statements that are not statements of historical fact, or that refer to expectations, projections, or other characterizations of future events or circumstances (including, without limitation, statements containing the words “believes,” “expects,” “anticipates,” “plans,” “intends,” “will,” “may,” “could,” “should,” “would,” “designed to,” “positioned to,” “potential,” “targeted,” “seeking,” “continues,” “strategy,” “opportunity,” “estimates,” “projects,” “forecasts,” “predicts,” “outlook,” “guidance,” or similar expressions, or the negative of such terms), are forward-looking statements. Forward-looking statements include, without limitation, the statements attributed to the Company’s management and to the Distributor in the quotations set forth in this press release, and statements regarding the anticipated benefits and revenue potential of the Agreement, whether or not they contain the words identified above. Forward-looking statements are based on Nexalin’s current expectations, assumptions, estimates, projections, and beliefs as of the date hereof and are subject to significant risks, uncertainties, and other factors, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied.

Forward-looking statements in this press release include, but are not limited to, statements regarding: the anticipated benefits, execution, and performance of the Agreement; the placement and fulfillment of initial and future purchase orders; the timing and launch of the clinical pilot program in Brazil; the initial 100-device commercialization program; the establishment and operation of a local manufacturing facility in Brazil; the anticipated per-device compensation and disposable royalties payable to Nexalin, including with respect to future clinical indications; the Distributor’s ability to satisfy the minimum revenue thresholds and other performance requirements under the Agreement; the transfer or maintenance of ANVISA regulatory approvals and the receipt of any additional regulatory approvals in the territory; the pursuit of government and public-sector opportunities; the size of the market opportunity in Brazil and the broader territory; the Company’s expectations regarding capital-light and recurring revenue; the Company’s anticipated transition from a pre-revenue research and development company to a revenue-producing company and the timing of any resulting revenue; the anticipated equal profit-sharing on qualifying private-sector transactions involving devices assembled in Brazil; the Company’s expectation of establishing a repeatable blueprint for, and executing, distribution partnerships in other international markets; the assumptions underlying the foregoing, including assumptions regarding market size, the prevalence of mental health disorders in the territory, the commercial significance of the clinical results described above, and the Company’s ability to supply encrypted circuit boards; and the Company’s broader clinical, regulatory, and commercial strategy, including its FDA De Novo pathway. These forward-looking statements are not guarantees of future performance, and no assurance can be given that the transactions and revenues contemplated by the Agreement will be realized on the anticipated timeline or at all.

Such risks include, but are not limited to: the Distributor’s ability and willingness to perform its obligations under the Agreement, including placement of purchase orders, payment obligations, satisfaction of performance requirements, and establishment of local manufacturing; the fact that the structured pricing framework for the first 100 Nexalin Sync devices does not obligate the Distributor to purchase any devices beyond the initial binding ten-device order, and that the Company may never recognize revenue from devices beyond that order; the risk that the clinical pilot program in Brazil is delayed beyond the targeted 90-day period or does not generate results supporting commercial adoption; the Distributor’s limited operating history with the Company’s products and its ability to fund the contemplated local manufacturing facility, on which substantially all of the Company’s anticipated per-device compensation and disposable royalty revenue depends; the parties’ ability to negotiate and execute the contemplated Licensing and Manufacturing Agreement; risks associated with reliance on a single distributor for the territory; risks relating to the maintenance, transfer, or receipt of ANVISA and other regulatory approvals, including the cooperation of the existing Brazilian regulatory holder and the risk that the existing ANVISA approval for the Nexalin Sync device is not transferred to, or maintained for the benefit of, the Company or the Distributor; the risk that the results of the single-site investigator-initiated trial at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo, including the reported 77.8% anxiety response rate, are not replicated in larger populations or in commercial use; the risk that the Company does not obtain marketing authorization through the FDA De Novo pathway on the anticipated timeline or at all; the Company’s history of operating losses and limited revenue and its need for additional capital; risks inherent in international operations, including foreign currency, tax, customs, import/export, sanctions, political, and economic risks in Brazil and the other countries in the territory, and anti-corruption and anti-bribery compliance risks in connection with government tenders and public-sector sales; competition from existing and new treatment alternatives; market acceptance of, and reimbursement for, the Company’s products; the Company’s ability to protect and enforce its intellectual property rights internationally; manufacturing, quality-system, and supply-chain risks, including the Company’s ability to supply the encrypted circuit boards required for every device; the outcome of any government tender or procurement processes; the Company’s ability to secure adequate funding on acceptable terms; and the Company’s ability to maintain compliance with the continued listing requirements of The Nasdaq Stock Market. Additional risks and uncertainties are described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, and in the Company’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings the Company makes from time to time with the U.S. Securities and Exchange Commission (the “SEC”), available free of charge at www.sec.gov. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com

Strong Follow-Up with Corporate and Government Prospects Met at GSX; Discussions with City Leaders Continue to Advance

Board and Shareholders Approve 1-for-20 Reverse Stock Split in Support of the Company’s Capital Markets Strategy

CEO to Discuss Business Update and Reverse Split Rationale on Investor Webinar Today at 11:00 AM Eastern Time

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today provided a business update highlighting positive leading indicators in its sales pipeline following its participation in Global Security Exchange (GSX) 2026. The Company also announced that its Board of Directors and shareholders have approved a 1-for-20 reverse stock split of the Company’s common stock. Founder and CEO Doron Kempel will discuss both topics in greater detail on the Company’s investor webinar being held today at 11:00 AM Eastern Time.

Business Update:

In the two weeks since GSX, Bond has seen strong follow-up from the corporate security leaders and government officials it met in Atlanta. As previously reported, more than 50 enterprise and government organizations with more than 10,000 employees each entered Bond’s pipeline at the event. Since then, the Company has found it easier to schedule meetings with prospective customers, those meetings have been more productive, and a greater share of them are advancing to the next stage of the sales process.

Bond’s government channel also continues to build. The Company is in ongoing discussions with mayors and senior officials in approximately 20 cities. In a city that currently funds Bond for its population, approximately 60% of the people offered the service have onboarded. We believe this to be a very high adoption rate for any service or product, especially across demographics, and is comparable to what we see in corporate adoption.

Bond believes this momentum reflects the credibility that independent validation brings to a new category. Research conducted by EY concluded that Bond’s Preventative Personal Security services generate a positive return on investment for corporations that offer Bond as a benefit to all employees, with an average annual benefit of between $180 and $280 per employee. Together with a growing base of reference customers that includes some of the world’s largest corporations and, more recently, cities, the Company believes it is positioned to extend adoption beyond early adopters to the early majority of the market. Bond expects this to result over time in a higher percentage of prospects adopting the service, shorter sales cycles and larger deal sizes, and is beginning to see early indications of each.

“GSX was our first broad awareness and lead generation campaign in five years, and the response since the event has been very encouraging,” said Doron Kempel, Founder and Chief Executive Officer of Bond. “Meetings are easier to schedule, the conversations are more substantive and more of them are moving forward. Combined with the discussions we are having with city leaders, we view these as positive leading indicators as Bond enters what we anticipate will be a period of enhanced growth.”

Reverse Stock Split:

Bond’s Board of Directors and shareholders have approved a 1-for-20 reverse stock split of the Company’s common stock. The Company is working with Nasdaq in accordance with its processes. The effective date and other implementation details have not yet been determined, and the Company intends to announce them through a Current Report on Form 8-K and a press release once they are final, which it currently anticipates will be within a matter of weeks.

“We believe there is a significant misalignment between the value of the business we are building and Bond’s current share price, and we view the reverse split as a positive step for the Company,” said Mr. Kempel. “The reverse split reduces our float and, at a higher share price, should make Bond’s shares eligible for purchase by institutional investors whose policies do not allow them to buy lower-priced stocks. We believe both are particularly significant as we enter an anticipated period of enhanced growth. The reverse split also assists with our Nasdaq compliance matters, which we expect to separately resolve organically by the end of the year.”

In July 2026, Nasdaq notified the Company that it was not in compliance with certain continued listing requirements, including Nasdaq’s $1.00 minimum bid price requirement. The Company was provided until January 11, 2027 to regain compliance with the applicable requirements.

Webinar:

Doron Kempel, Founder and CEO, will host a live investor webinar today, October 1, 2026, at 11:00 AM Eastern Time to discuss the business update and the rationale for the reverse stock split in greater detail.

Date: Thursday, October 1, 2026
Time: 11:00 AM Eastern Time
Registration Link: https://ourbond.zoom.us/webinar/register/WN_jybQ2AHqSVuv3DkTETWTbA#/registration

About Bond

Bond is an international company headquartered in New York City — with command centers around the world — that is redefining personal security through its AI-powered Preventative Personal Security platform. The company has invested more than $100 million to date in its technology, operations, and global expansion.

Bond offers personal security to more people than any other company globally. Bond is trusted by leading corporations, cities, and universities, and has already supported more than 1.25 million security service requests, including over 10,000 emergencies and life-saving interventions. Bond operates in 28 countries and growing, positioning itself as a new global standard for personal security and peace of mind. Additional information about the Company is available at: www.ourbond.com.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading “Risk Factors” in our most recent Registration Statement on Form S-1, under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K, or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC, copies of which are available on the SEC’s website at www.sec.gov. Our Bond, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise that occur after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
212-671-1020
OBAI@crescendo-ir.com

Houston, Texas, Oct. 01, 2026 (GLOBE NEWSWIRE) — Battalion Oil Corporation (NYSE American: BATL) (“Battalion” or the “Company”) today announced that John “Brad” Juneau has joined its Board of Directors, effective September 30, 2026. Mr. Juneau brings more than 40 years of extensive experience in oil and gas exploration and development, executive management, public company board service, and mergers and acquisitions. In connection with Mr. Juneau’s appointment as an independent director, the Company’s Board of Directors was expanded to five members.

Mr. Juneau’s appointment follows the Board’s previously stated intention, following director changes announced in March 2026, to identify and appoint additional independent directors who would further strengthen the Board’s composition and governance. His appointment maintains a majority-independent Board.

Mr. Juneau is the founder and sole manager of Juneau Exploration, L.P. (“Juneau Exploration”), a private prospect generation and exploration company. He currently serves as a director of Talos Energy Inc. (“Talos”), where he is a member of the Compensation Committee and the Safety, Sustainability and Corporate Responsibility Committee, and also serves as a director of Contango Silver & Gold Inc. (“Contango Ore”), having previously served as its Chairman. He joined the Talos board in 2018 following its combination with Stone Energy Corporation, where he had served as a director since 2017.

In 1999, Mr. Juneau co-founded Contango Oil & Gas Company (“Contango”) with the late Kenneth R. Peak. Contango discovered and developed several new fields in South Texas and the Gulf of Mexico, including the Dutch and Mary Rose fields, increasing Contango stock price from $0.20/share to a high of $75/share. Previously, Mr. Juneau spent 11 years at Zilkha Energy Company (“Zilkha”), joining as Vice President of Operations before rising to Senior Vice President of Exploration, where he built and led the in-house technical team responsible for generating the company’s offshore Gulf of Mexico prospects using regional 3D seismic. Zilkha was sold to Sonat, Inc. in 1998 for $1.5 billion.

Through Juneau Exploration, Mr. Juneau led the 2009 gold discovery in eastern interior Alaska that became the Manh Choh project, which was later spun out into Contango Ore and commenced production in 2024. Juneau Exploration currently manages an ultra-deep natural gas project in South Louisiana and is partnered on an oil exploration project on Alaska’s North Slope. Mr. Juneau holds a B.S. in Petroleum Engineering from Louisiana State University.

Management Comments

“Brad has spent four decades finding and developing hydrocarbons and building companies around those discoveries, and just as often, building them toward a well-timed sale or combination, from Zilkha Energy’s sale to Sonat to Stone Energy’s combination with Talos,” said Matt Steele, Chief Executive Officer. “That is precisely the kind of accretive, consolidation-minded experience we want on our Board. His technical expertise as a petroleum engineer, his proven record of creating value for shareholders, and his public company board experience make him a valuable addition as we execute our strategy. We are pleased to welcome him to the Board.”

“Battalion has a quality asset base that we can build on and a management team that can execute. Together we can create substantial shareholder value. I’ve spent my career finding value in overlooked positions and helping build them into something bigger. I look forward to working with the Board and management toward that same outcome for Battalion’s shareholders,” said Mr. Juneau.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not strictly historical statements constitute forward-looking statements. Forward-looking statements in this release include, among others, statements about the anticipated contributions of Mr. Juneau to the Board and the Company’s strategy. Forward-looking statements may often, but not always, be identified by the use of words such as “expects,” “believes,” “intends,” “anticipates,” “plans,” “estimates,” “projects,” “potential,” “possible” or “probable,” or statements that certain actions, events or results “may,” “will,” “should” or “could” be taken, occur or be achieved. Forward-looking statements are based on current beliefs and expectations, involve certain assumptions or estimates, and are subject to risks and uncertainties that could cause actual results to differ materially from those reflected in the statements. These risks include, but are not limited to, those set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, its subsequent Quarterly Reports on Form 10-Q, and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov or through the Company’s website at www.battalionoil.com. Readers should not place undue reliance on any such forward-looking statements, which are made only as of the date hereof. The Company has no duty, and assumes no obligation, to update forward-looking statements as a result of new information, future events or changes in the Company’s expectations.

About Battalion

Battalion Oil Corporation is an independent energy company engaged in the acquisition, production, exploration and development of onshore oil and natural gas properties in the United States.

CONTACT: BATTALION OIL CORPORATION
Matthew B. Steele
Chief Executive Officer
832-538-0300 | www.battalionoil.com

CULVER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today announced its participation in the 2026 Steam Autumn Sale, bringing limited-time discounts across its portfolio from October 1 through October 8, 2026.

The Steam Autumn Sale is one of Steam’s four major annual platform-wide promotional events, providing developers and publishers with expanded visibility to millions of PC players. Timed ahead of the Halloween holiday season, the seasonal promotion provides an opportunity to drive incremental visibility and engagement across the Company’s existing catalog while expanding exposure to new audiences during a high-demand period for horror content. Seasonal Steam sale events have historically driven meaningful engagement for Snail Games’ catalog, increasing player acquisition, unit sales, and revenue contributions while expanding and re-engaging communities across established and emerging titles.

This year’s sale highlights some of Snail Games’ strongest-performing franchises, including ARK: Survival Ascended, Bellwright, and PixARK, while reintroducing players to a curated lineup of atmospheric horror titles from Snail Games’ indie publishing branch, Wandering Wizard, including Castle of Secrets, Chasmal Fear, and The Cecil: The Journey Beyond. Alongside discounted titles, Snail Games is encouraging players to wishlist the Company’s upcoming horror releases on Steam, including Veil of Madness, Whispers of West Grove, and Dead Party. By pairing seasonal catalog monetization with wishlist growth for upcoming releases, the Company seeks to capitalize on traffic built from the seasonal event to extend the commercial lifecycle of existing IP, drive awareness for upcoming titles, and maximize the long-term value of its game portfolio.

For the latest discounts and participating titles, visit the Snail Games publisher page on Steam during the Steam Autumn Sale, running October 1 through October 8, 2026.

For creators interested in collaborations please reach out to creatordirect@noiz.gg

About Snail Games
Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. These forward-looking statements include information about possible or assumed future results of Snail Games’ business, financial condition, results of operations, liquidity, plans and objectives. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, the following statements: the sale spotlighting the horror portfolio of Snail Games’ indie publishing branch, Wandering Wizard, including Castle of Secrets, Chasmal Fear, and The Cecil: The Journey Beyond; the seasonal promotion providing an opportunity to drive incremental visibility and engagement across the Company’s existing catalog while expanding exposure to new audiences during a high-demand period for horror content; Snail Games bringing previously released titles back into the spotlight, potentially generating new interest to games that have already launched while introducing them to new audiences. Further information on risks, uncertainties and other factors that could affect Snail Games’ financial results and business include the market acceptance of Snail Games’ portfolio; the success of the 2026 Steam Autumn Sale and the ability to drive incremental visibility and engagement from the sale, Snail Games’ ability to strengthen its gaming portfolio’s visibility; Snail Games’ ability to expand and grow its franchise and increase its revenue; retain its key employees and maintain its Nasdaq listing; and the risks that are included in its filings with the Securities and Exchange Commission (the “SEC”) from time to time, including its annual reports on Form 10-K and quarterly reports on Form 10-Q filed, or to be filed, with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those expressed or implied in the forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on management’s beliefs and assumptions and on information currently available to Snail Games, and Snail Games does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
SNAL@gateway-grp.com

WUXI, China, Oct. 01, 2026 (GLOBE NEWSWIRE) — HUHUTECH International Group Inc. (NASDAQ: HUHU) (“HUHUTECH” or the “Company”), a system integration provider that designs and implements integrated facility management systems and industrial automation monitoring systems for the optoelectronic, semiconductor, telecom, and logistics industries, today provided a commercialization update on the HB-800, its in-house developed high-end vacuum furnace for MOCVD (Metal-Organic Chemical Vapor Deposition) susceptor cleaning and precision heat treatment applications.

Since announcing the HB-800’s technology finalization in June 2026, the Company has engaged with five  optoelectronics manufacturers in the Yangtze River Delta region, including publicly listed companies and subsidiaries of publicly listed groups active in Micro LED chips, VCSEL laser chips and related compound semiconductor devices. HUHUTECH’s engineering team has conducted on-site assessments at these customers’ manufacturing facilities, submitted equipment quotations, and held multiple rounds of technical discussions to refine the HB-800 configuration to each customer’s process and production requirements.

Requirements identified through these engagements fall into two categories, consistent with the Company’s dual commercial model: technical upgrades and retrofits of customers’ existing installed equipment, and procurement of new HB-800 units. HUHUTECH is actively pursuing opportunities in both categories. With discussions advancing at varying stages, the Company now expects to execute its first HB-800 purchase agreement before the end of 2026. Discussions remain ongoing, and there can be no assurance that any purchase agreement will be executed on the anticipated timeline, or at all.

“Over the past four months, our team has been inside our prospective customers’ fabs, studying their existing equipment and working through their specific process requirements. That work has shaped both our quotations and several refinements to the HB-800 itself,” said Mr. Yujun Xiao, Chief Executive Officer of HUHUTECH. “Optoelectronics manufacturers run MOCVD capacity continuously, which creates recurring demand for susceptor cleaning and heat treatment. Working with multiple manufacturers across both new equipment and retrofit opportunities gives us a solid foundation to secure our first order and build the HB-800 into a meaningful, higher-margin business line alongside our engineering services.”

About HUHUTECH International Group Inc.

HUHUTECH International Group Inc. (Nasdaq: HUHU) is a professional system integration provider that designs and implements integrated facility management systems and industrial automation monitoring systems for the optoelectronic, semiconductor, telecom, and logistics industries. Through its operating subsidiaries in the People’s Republic of China, Japan, the United States, Germany, and Singapore, the Company delivers customized fixed-price engagements spanning project planning, system coding, hardware installation and configuration, and also supplies related equipment. HUHU China holds a first-class construction enterprise qualification and maintains “high-tech enterprise” tax status in the PRC through December 2028. The Company is headquartered in Wuxi, Jiangsu Province, China. For more information, visit https://ir.huhutech.com.cn.

Safe Harbor Statement

Certain statements in this announcement are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. All statements other than statements of historical facts included in this announcement are forward-looking statements. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions, or strategies of the Company regarding the future. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based solely on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. Forward-looking statements are based on current expectations and assumptions that, while considered reasonable, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. The Company’s actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include the risks and uncertainties described in the Company’s annual report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “Commission”) on April 28, 2026, and the Company’s other filings with the Commission. Except as required by law, the Company undertakes no obligation to update any forward-looking statement, whether written or oral, publicly, that may be made from time to time, whether as a result of new information, future developments, or otherwise.

Company Contact

Email: ir@huhutech.com

Website: www.huhutech.com

Investor Relations Contact

Matthew Abenante, IRC
President
Strategic Investor Relations LLC
Phone: +1 (347) 947-2093
Email: matthew@strategic-ir.com

Web: www.strategic-ir.com

# # #

DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the completion of the first Site Initiation Visit (“SIV”) associated with the commencement of a clinical study designed to support a label expansion of the Company’s FDA-cleared DeepView System™ for Burn Indication to include burns involving the head, hands and feet.

The SIV was conducted at Pinderfields Hospital, Wakefield, UK under the leadership of Principal Investigator Dr. Preetha Muthayya, Consultant Burns and Plastic Surgeon and Clinical Lead for Burns. Pinderfields Hospital is part of the Mid Yorkshire Teaching NHS Trust and provides expert care for adult and pediatric patients with serious and life-threatening burn injuries.

Following the completion of all applicable site-readiness requirements, the first SIV represents the operational launch of the clinical study and enables Pinderfields Hospital to begin patient enrollment.

The study is intended to generate additional clinical evidence to support the use of the DeepView System in these anatomically complex burn areas, where timely and accurate assessment of a burn-wound’s healing potential can be particularly important to treatment planning.

“Completion of the first site initiation visit is an important step in advancing our strategy to broaden the potential clinical utility of the DeepView System,” said Vincent Capone, Chief Executive Officer of Spectral AI. “Burns involving the head, hands and feet present unique clinical considerations, and we believe the ability to provide clinicians with rapid, objective information regarding healing potential in these anatomically complex areas could be especially valuable. This study builds on the clinical and regulatory foundation established by our FDA-cleared DeepView System for Burn Indication and reflects our commitment to expanding the technology’s applicability for burn-care providers and their patients.”

Mr. Capone concluded, “We are grateful for the commitment of our clinical collaborators and the patients who participate in this important research, and look forward to advancing the study in support of a potential label expansion.”  

Dr. Muthayya said, “We are delighted to be the first site to complete our site initiation and very much look forward to enrolling patients into this label expansion study.”

About the Clinical Study

“Clinical Study of the DeepView AI-System for Assessment of Thermal Burn Healing Potential in Hands, Feet and Head/Face Training and Validation Label Expansion Study.”​

The prospective training and validation study is expected to enroll adult and pediatric patients with qualifying thermal burns involving the hands, feet or head/face. Participants will be imaged with the DeepView System within 72 hours of injury, with healing outcomes assessed through 21 days. The resulting image dataset will support both algorithm training and independent validation of system performance, with the DeepView System used in a blinded, observational capacity and not to direct patient care. The study will be conducted at multiple sites in the UK and is expected to be completed in 2027.

About the DeepView System™

Spectral AI’s DeepView System is a non-invasive, predictive medical device that combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of areas within burn wounds. It was granted De Novo Classification by the U.S. Food and Drug Administration (“FDA”) in May 2026 and received its initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024. The DeepView System provides physicians with an immediate, data-driven assessment of whether areas within burn wounds are unlikely to heal within 21 days and may require significant medical intervention, enabling earlier and more informed treatment decisions. The image acquisition takes 0.2 seconds, and all image processing and AI model classification takes approximately 20 to 25 seconds. The DeepView System is trained and tested against a proprietary and clinically validated database of over 340 billion pixels of burn wound image data.

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. For more information about the DeepView System, visit www.spectral-ai.com.

The Company’s contract with the Biomedical Advanced Research and Development Authority (“BARDA”) is held and performed through its wholly owned subsidiary, Spectral MD. References to the contract, associated awards, related revenue, business opportunities, obligations, and other relevant factors should be understood to refer to Spectral MD as the contracting party unless otherwise indicated.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. 

Investors:
The Equity Group 
Devin Sullivan
Managing Director 
Devin.Sullivan@theequitygroup.com

Conor Rodriguez
Associate  
Conor.Rodriguez@theequitygroup.com

Drone as a Service generated $8.6 million, or nearly 93% of Q2 revenue, as the Company expanded its operating platform and advanced its defense technology portfolio

VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech” or the “Company”), a technology solution provider specializing in AI-powered drones, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, today provides a business update and future outlook in a letter to shareholders from CEO Shaun Passley, Ph.D. Unless otherwise indicated, all financial figures are expressed in Canadian dollars.

To our valued shareholders,

ZenaTech continues its evolution from a technology development company with a software revenue base to a diversified, multi-product and vertically integrated operating company with a scalable Drone as a Service platform, and advancing commercial, government and defense drone technology portfolio, and an enterprise software business.

I am proud of what we accomplished during the first half of 2026. We continued to execute our business plan, scale our DaaS operations and advance our drone and software platforms for business, government and defense markets.

Second-quarter revenue reached $9.3 million, up 316% year over year, while revenue for the first six months reached $17.7 million, up 425% from the comparable period last year. First-half revenue also exceeded our full-year 2025 revenue of $12.9 million by approximately 37%. Drone as a Service remained our primary revenue engine, contributing $8.6 million, or nearly 93% of total revenue in the quarter, and $16.4 million during the first half.

We have now delivered seven consecutive quarters of sequential revenue growth since Q4 2024. Quarterly revenue increased more than 13 times over that period, from approximately $0.7 million in Q4 2024 to $9.3 million in Q2 2026.

In June 2026, ZenaTech was added to the Russell 3000® Index, an important market-recognition milestone as we continue to expand the Company.

Our Q2 operating expenses increased with our larger workforce, acquired operations, sales and marketing activity, technology development and public-company costs. We recognize that scaling revenue must ultimately translate into improved operating leverage. Our focus is therefore not only on adding locations, but also on integrating them, deploying drone-enabled workflows and expanding higher-value data and analytics services.

Following our May financing, we ended the quarter with $12.2 million in cash, $34.6 million in combined cash and marketable securities, and $24.3 million in working capital. Total assets increased 50% to $149.3 million and shareholders’ equity increased 34% to $91.4 million. These resources provide flexibility to fund integration, product development and disciplined acquisitions, while we remain focused on careful capital allocation.

Drone as a Service

The scale of our operating platform continues to expand. In Q2 2026, we completed four land survey and legacy service business acquisitions, bringing our cumulative DaaS acquisition count to 24 at June 30. Subsequent transactions increased that count to 29 to date and expanded our presence into additional sectors and regions, including Alberta, Ohio, Idaho and, most recently, Georgia. ZenaTech’s DaaS operations now have a physical presence in 14 U.S. states. We also expanded our corporate footprint with offices in South Korea and the United Kingdom, while our broader DaaS operations and acquisition activity extend across the U.S., Canada, the UK and Australia.

We chose land surveying and related engineering services deliberately. These are essential, fragmented industries facing a shortage of licensed professionals, while many workflows remain manual and dependent on decades-old processes. By combining established local operators and customer relationships with drones, LiDAR, centralized data processing and analytics, we believe we can increase field capacity, shorten project timelines and improve data and precision. For customers, that can mean faster and more useful information. For shareholders, it creates a platform through which technology, shared services and new offerings can be deployed across a growing revenue base.

Our objective is to build a scaled, technology-enabled global Drone as a Service platform. We acquire established operating companies with licensed professionals, existing customers and specialized expertise, then connect them with ZenaDrone technology, software, AI, analytics and our vertically integrated manufacturing capabilities. Each acquisition adds an existing revenue base upon consolidation. As integration progresses, we believe drone-enabled workflows can reduce costs per job, increase capacity and support margin improvement.

Scale matters because each new location expands the customer base into which we can deploy differentiated technology and data services and broadens the types of contracts we can pursue. We will continue to target acquisitions in sectors ready for drone-enabled modernization as we enter new U.S. states and international markets. At the time of our Q2 results announcement, signed acquisition offers across the U.S., Canada and Australia, if completed, were expected to contribute approximately $40 million in revenue during the first 12 months following closing.

Defense Technology Progress

Our defense technology portfolio is an important component of our long-term strategy, and we continue to advance product development, certification and customer engagement as demand for commercial and defense drone solutions grows.

The ZenaDrone 1000, IQ Nano and IQ Square have advanced into the cybersecurity phase of the Blue UAS certification process, while the IQ Quad is also progressing toward certification. Blue UAS certification supports eligibility for U.S. government and defense procurement. We are also moving from internal development toward customer-facing demonstrations. We have received our first confirmed U.S. government defense agency demonstration request and are planning demonstrations involving the IQ Nano, ZenaDrone 1000 and IQ Square for applications including inspections, surveys, specialized cargo, reconnaissance and inventory management. We believe this progress strengthens our ability to pursue future pilots and potential contracts.

We continue to build out our Counter-UAS platform to offer cost-effective solutions. Low-cost hostile drones can be extraordinarily expensive to counter using traditional intercept methods. The Interceptor P-1 is our low-cost, one-way autonomous interceptor designed to physically engage hostile drones, with a target selling price of under US$5,000. It has entered flight testing. We have also advanced our IQ Aqua underwater mine-detection drone into U.S. field testing in Florida and are progressing development of the larger gas-powered ZenaDrone 2000 and IQ Glider autonomous maritime launch and refueling platform. Together, these technologies form part of a broader integrated Counter-UAS architecture intended to be supported by Zena AI and our research involving detection and swarm-command capabilities.

ZenaDrone has also begun in-house flight testing of custom-designed printed circuit boards manufactured by our Taiwan-based Spider Vision Sensors subsidiary and integrated at our UAE facility, advancing our vertical-integration strategy toward NDAA-compliant drones and Blue UAS certification.

Geographically, we are developing capabilities for U.S. and allied defense markets, including potential NATO and Gulf-state opportunities. Our Ukraine-based manufacturing and testing operation is being established with a planned focus on Counter-UAS and interceptor drones, and we registered Phoenix Aero as our Western Ukraine-based company.

Enterprise Software

Enterprise SaaS revenue was $702,315 in Q2, an increase of approximately 6% from the prior-year quarter. First-half Enterprise SaaS revenue was $1.29 million, compared with $1.39 million a year earlier. During the quarter, we added NOW Solutions, an HR and payroll software business serving government and institutional customers.

We also announced Zoo Office™, the next evolution of our enterprise software strategy. Our vision is an AI-powered enterprise productivity platform that will include the Company’s existing 13 software brands together with new applications under development. It is intended to provide an integrated business environment in which AI can understand organizational context, automate repetitive workflows, execute tasks and support better decisions.

We have also expanded ZenaWorx virtual design and construction progress monitoring with digital-terrain-modeling capabilities and signed the Company’s first paying customer in the AI data-center construction market.

Outlook for the Remainder of 2026

As we move through the second half of 2026, we believe we are positioned to continue building the business. Our priorities remain integrating and scaling our platforms, converting technology investment into revenue, and continuing the disciplined M&A activity that has driven our growth.

In DaaS, we are working to close transactions covered by signed acquisition offers while continuing to integrate acquired survey, inspection and power-washing businesses into drone-based delivery. Our objectives include reducing the cost per survey and per job, increasing capacity and geographic reach, supporting margin expansion, and introducing additional data and analytics services with centralized processing.

In drone technology and defense, we are advancing product development, the Blue UAS certification process and engagement with U.S. defense agencies. These activities are intended to support additional demonstration requests, potential procurement-list inclusion, pilots and future government revenue. We are also progressing our Counter-UAS and interceptor programs and establishing Ukraine-based testing and manufacturing capabilities to support product-development objectives.

Our manufacturing priorities include further commissioning facilities, expanding production capabilities and growing manufacturing and testing teams across Mesa, Arizona; Sharjah, UAE; and Taipei, Taiwan.

In enterprise software, we are continuing the rollout of Zoo Office™, our planned AI-powered enterprise productivity platform incorporating 13 existing software brands and designed to support future Enterprise SaaS revenue opportunities.

Finally, we will continue to manage our balance sheet carefully as we fund organic growth, integrate acquisitions and pursue additional disciplined transactions.

ZenaTech is a very different company than it was a year ago. We have moved from primarily developing software and technologies to building a larger operating platform with revenue, customers, acquired businesses, manufacturing capabilities, software products and a growing defense opportunity pipeline.

I am proud of what we have accomplished to date and the results we have delivered. We remain committed to building long-term shareholder value as we scale the business. I am grateful for your continued support and confidence, and I look forward to sharing our progress throughout the remainder of 2026.

Sincerely,

Shaun Passley, Ph.D.

Chief Executive Officer

ZenaTech, Inc.

Additional information is available in ZenaTech’s Form 6-K filing on the SEC EDGAR website.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries including land surveys and inspections, driving drone-based scalable and recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for agriculture and logistics, as well as ISR, cargo, and counter-UAS applications for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, and the IQ Aqua for underwater applications. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors, and Media: Linda Montgomery ZenaTech 312-241-1415 investors@zenatech.com

Investors: Michael Mason CORE IR investors@zenatech.com

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks and uncertainties disclosed under the heading “Risk Factors” in the Company’s Form F-1, Form 20-F and other filings filed with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at www.sec.gov. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.